Back
About
PaxMedica, Inc. is an early-stage biotech company developing drugs to treat extremely complex and widespread neurological disorders.
Two of PaxMedica's main research efforts are focused on therapies for currently incurable conditions related to nervous system dysfunction and gene damage.
The drug candidate PAX-101 is in Phase IIa clinical trials for the treatment of autism spectrum disorder. Data from February 2021 showed a positive effect of PAX-101.
The drug candidate PAX-102 is in preclinical trials for the treatment of FXTAS syndrome (which causes severe brain damage and is the most common cause of mental retardation in men). This drug also theoretically may be effective in treating autism and other disorders.
______________________________________
Number of employees: 4-10
______________________________________
Headquarters location: Tarrytown, New York, USA
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.